Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sopharma AD-SofiaWAR:SPH +0.28%67 Cyclically Adjusted PB Ratio is 0.64 as of Aug. 07, 2026, which is 71% below its 10-year median of 2.22. GuruFocus rates WAR:SPH with a GF Score™ of 67/100 and a GF Value™ of zł13.28 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 91 Medical Distribution companies, Sopharma AD-Sofia ranks better than 75.82% on this metric.
The historical rank and industry rank for Sopharma AD-Sofia's Cyclically Adjusted PB Ratio or its related term are showing as below:
WAR:SPH'
s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.65 Med: 2.22 Max: 3
Current: 0.72
During the past years, Sopharma AD-Sofia's highest Cyclically Adjusted PB Ratio was 3.00. The lowest was 0.65. And the median was 2.22.
WAR:SPH's Cyclically Adjusted PB Ratio is ranked better than 75.82% of 91
companies
in the Medical Distribution industry
Industry Median: 1.13
vs WAR:SPH: 0.72
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Sopharma AD-Sofia's adjusted book value per share data for the three months ended in Mar. 2026 was zł4.249. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is zł11.23 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Sopharma AD-Sofia (WAR:SPH) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Sopharma AD-Sofia Cyclically Adjusted PB Ratio Related Terms
Sopharma AD-Sofia Cyclically Adjusted PB Ratio Historical Data
* Premium members only.
The historical data trend for Sopharma AD-Sofia's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sopharma AD-Sofia Cyclically Adjusted PB Ratio Chart
WAR:SPH vs MCK, COR, CAH: Cyclically Adjusted PB Ratio Comparison
For the Medical Distribution subindustry, Sopharma AD-Sofia's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sopharma AD-Sofia Cyclically Adjusted PB Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sopharma AD-Sofia's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Sopharma AD-Sofia's Cyclically Adjusted PB Ratio falls into.
Sopharma AD-Sofia Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
Sopharma AD-Sofia's Cyclically Adjusted PB Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 0.64 mean?
Sopharma AD-Sofia (WAR:SPH) has a Cyclically Adjusted PB Ratio of 0.64 as of Aug. 07, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Sopharma AD-Sofia and its competitors. This is 71% below median its historical median of 2.22. Over the past decade, Sopharma AD-Sofia's Cyclically Adjusted PB Ratio has ranged from 0.65 to 3.00. According to the industry distribution chart, Sopharma AD-Sofia ranks #22 out of 91 companies in the Medical Distribution industry, placing it in the top 24.2%.
Is Sopharma AD-Sofia's Cyclically Adjusted PB Ratio too high?
Sopharma AD-Sofia's current Cyclically Adjusted PB Ratio of 0.64 is 71% below median its 10-year median of 2.22. Over the past 10 years, this metric has ranged from a low of 0.65 to a high of 3.00. The Medical Distribution industry median Cyclically Adjusted PB Ratio is 1.13. Sopharma AD-Sofia's value of 0.64 is 43.4% below this industry median. Based on the distribution chart, Sopharma AD-Sofia ranks #22 out of 91 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Sopharma AD-Sofia has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sopharma AD-Sofia's Cyclically Adjusted PB Ratio compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Sopharma AD-Sofia ranks #22 out of 91 companies for Cyclically Adjusted PB Ratio. This places Sopharma AD-Sofia in the top 24% of its industry — outperforming the majority of peers. The industry median Cyclically Adjusted PB Ratio is 1.13. Sopharma AD-Sofia's value of 0.64 is 43.4% below this benchmark. Historically, Sopharma AD-Sofia's own Cyclically Adjusted PB Ratio has ranged from 0.65 to 3.00 over the past decade. While the company's 10-year median is 2.22 vs. the industry median of 1.13, Sopharma AD-Sofia has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Medical Distribution company?
The median Cyclically Adjusted PB Ratio among Medical Distribution companies is 1.13, based on 91 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sopharma AD-Sofia's current Cyclically Adjusted PB Ratio of 0.64 is 43.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Sopharma AD-Sofia and its competitors. For the Medical Distribution industry, the median Cyclically Adjusted PB Ratio is 1.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sopharma AD-Sofia's current Cyclically Adjusted PB Ratio is 0.64, which is 71% below median its own 10-year median of 2.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma AD-Sofia stock overvalued right now?
Based on GuruFocus' analysis, Sopharma AD-Sofia (WAR:SPH) is currently considered Possible Value Trap. The stock's GF Value™ is zł13.28, compared to a current price of zł7.22 — trading 45.6% below its estimated fair value. The current Cyclically Adjusted PB Ratio is 0.64, which is 71% below median its 10-year median of 2.22 and 43.4% below the Medical Distribution industry median of 1.13. Sopharma AD-Sofia's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For Sopharma AD-Sofia (WAR:SPH), the current Cyclically Adjusted PB Ratio is 0.64 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sopharma AD-Sofia (WAR:SPH) Overvalued in 2026?
Based on GuruFocus' analysis, Sopharma AD-Sofia stock appears to be undervalued.
The current stock price of zł7.22 is trading 45.6% below its estimated GF Value™ of zł13.28.
GuruFocus considers Sopharma AD-Sofia to be Possible Value Trap.
Key valuation signals for WAR:SPH:
Cyclically Adjusted PB Ratio: 0.64 (71% below median its 10-year median of 2.22)
GF Value™: zł13.28 vs. price of zł7.22 (45.6% below fair value)
Industry Position: 43.4% below the Medical Distribution median (#22 of 91)
No single metric tells the full story. See the WAR:SPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
67GF Score
Get the complete analysis for WAR:SPH
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SPH has been successfully added to your 
